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Neurobiology of Disease
Induction of Brain Region-Specific Forms of Obesity
by Agouti
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Joost Verhaagen,4 and Roger A. H. Adan1
1Rudolf Magnus Institute of Neuroscience, Department of Pharmacology and Anatomy, University Medical Centre Utrecht, 3584 CG Utrecht, The
Netherlands, 2Division of Neuroendocrinology, Department of Animal Physiology, University of Groningen, 9750 AA Haren, The Netherlands, 3Department
of Pediatrics and Genetics, Howard Hughes Medical Institute, Stanford University, Stanford, California 94305, and 4Graduate School Neurosciences
Amsterdam, Netherlands Institute for Brain Research, 1105 AZ Amsterdam, The Netherlands
Disruption of melanocortin (MC) signaling, such as by ectopic Agouti overexpression, leads to an obesity syndrome with hyperphagia,
obesity, and accelerated body weight gain during high-fat diet. To investigate where in the brain disruption of MC signaling results in
obesity, long-termAgouti expressionwas induced after local injections of recombinant adeno-associated viral particles in selected brain
nuclei of adult rats. Agouti expression in the paraventricular nucleus, a hypothalamic regionwith ahighdensity ofMC receptors, induced
acute onset hyperphagia and rapid weight gain that persisted for at least 6 weeks. In contrast, obesity and hyperphagia developed with a
3week delay whenAgouti was expressed in the dorsalmedial hypothalamus. Agouti expression in the lateral hypothalamus (LH) did not
affect food intake and body weight during regular diet, despite the presence ofMC receptors in this region. However, during exposure to
a high-fat diet, animals with Agouti expression in the LH exhibited a marked increase in body weight. Here we show that the LH is
important for the protection against diet-induced obesity by controlling caloric intake during consumption of a high-fat diet. Together,
this studyprovides evidence thatdifferent aspects of theAgouti-inducedobesity syndrome, suchashyperphagia anddiet responsiveness,
aremediated bydistinct brain regions andopens challenging opportunities for further understanding of pathophysiological processes in
the development of the obesity syndrome.
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Introduction
Genetic studies have shown that the yellow coat color and the
obesity syndrome in rodents with ectopic Agouti overexpression
are regulated independently by Agouti antagonism of the
melanocyte-stimulating hormone receptor-1 (MC1-R) and of
the MC4-R, respectively (Duhl et al., 1994; Lu et al., 1994; Fan et
al., 1997;Huszar et al., 1997). AlthoughAgouti antagonismof the
MC1-R in the skin causes a yellow fur by switching eumelanin
into phaeomelanin pigment synthesis (Ollmann et al., 1998), it is
not fully understood where and howAgouti expression generates
the obesity syndrome. Because pharmacological blockade or ge-
netic disruption of the MC4-R lead to hyperphagia and obesity
(Huszar et al., 1997; Kim et al., 2000; Adage et al., 2001) and the
MC4-R is expressed in distinct brain areas (Gantz et al., 1993;
Mountjoy et al., 1994; Kishi et al., 2003), it is hypothesized that
central Agouti expression accounts for hyperphagia and subse-
quent body weight gain within the yellow obese syndrome.
Although the melanocortin signaling pathway is clearly in-
volved in body weight control by affecting food intake (Fan et al.,
1997; Huszar et al., 1997) and diet responsiveness (Butler et al.,
2001), it is poorly understoodwhether one or different brain sites
mediate thoseMC effects. Other investigators have used intranu-
clear injection of melanocortin ligands to study these questions
(Kim et al., 2000; Wirth et al., 2001); however, this approach is
limited by the relatively short time of action of these compounds
in tissues, which does not allowmeasurement of obesity develop-
ment over weeks or months. To study the relationship between
MC pathway involvement in the obesity syndrome and the func-
tional anatomy of the MC system, we locally interfered with
melanocortin receptor signaling using vector directed gene ex-
pression technology.
The paraventricular nucleus of the hypothalamus (PVN) con-
tains a high density of MC4-Rs that have been proposed to me-
diate MC-induced changes in food intake. For example, single
injections of MC4-R ligands in the PVN alter food intake and
body weight in rodents (Kim et al., 2000; Wirth et al., 2001).
Recent studies suggest that the dorsal medial hypothalamus
(DMH) is also involved in the regulation of hyperphagia (Chen et
al., 2004). In addition, based on the outcome of classical lesion,
electric stimulation, and electrophysiological studies, the lateral
hypothalamus (LH) has long been implicated in the regulation of
energy metabolism (Anand and Brobeck, 1951; Delgado and
Anand, 1953; Katafuchi et al., 1985). This idea is corroborated by
the recent identification of LH neurons that express neuropep-
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tides involved in eating behavior, such as hypocretins/orexins
and the melanin-concentrating hormone (MCH) (Zamir et al.,
1986; de Lecea et al., 1998; Sakurai et al., 1998). PVN, DMH, and
LH neurons express moderate to high levels of MC4-R (Gantz et
al., 1993; Mountjoy et al., 1994; Kishi et al., 2003). As a first step
toward understanding where in the brain disruption of MC sig-
naling results in obesity, rats with PVN, DMH, or LH injections
of either recombinant adeno-associated virus (rAAV)-Agouti or
rAAV-enhanced green fluorescent protein (EGFP) were moni-
tored when exposed to a regular or a high-fat diet.
Materials andMethods
Recombinant adeno-associated viral vector production. Construction of
pTR-cytomegalovirus (CMV)-EGFP has been described previously
(Eaton et al., 2002). Agouti was PCR amplified using as template a plas-
mid containing the mouse Agouti cDNA (paE65; a kind gift from Roger
D. Cone, Oregon Health and Science University, Portland, OR) using
oligos 5aagcttgagatctgccgcaccatggatgtcacccg and 5gaagaagctagctcag-
cagttggggttg. A (BglII andNheI digested) fragment containing the Agouti
cDNA was cloned into BamHI and SpeI digested pTR-CMV-EGFP (this
removes the EGFP cDNA; correct sequence of Agouti was confirmed by
sequence analysis), which generated pTR-CMV-Agouti. Next, rAAVwas
generated via a two-component, adenovirus-free packaging systemusing
the helper plasmid pDG [kindly provided by J. Kleinschmidt, Deutsches
Krebsforschungszentrum, Heidelberg, Germany (Grimm et al., 1998)].
Recombinant AAV particles were produced by the method described
previously by Hermens et al. (1999). Briefly, the vector plasmid pTR-
CMV-Agouti or pTR-CMV-EGFP and the helper plasmid pDG were
cotransfected into human embryonic kidney (HEK) 293T cells using
calciumphosphate precipitation (molar plasmid ratio, 1:1). Themedium
was replaced after 6 hr by freshDMEMcontaining 10%FCS, and the cells
were incubated for 48 hr at 37°C and 5% CO2. Next, the cells were
dislodged, harvested, and freeze-thawed three times to release the AAV-
particles from the cells. Cell debris was removed using low-speed centrif-
ugation. The supernatant was loaded on a Matrex Cellufine sulfate bead
column (Amicon, Danvers, MA). After several washings with PBS, the
virus was eluted from the column with PBS containing 1 M NaCl. Next,
viral particles were banded on an iodixanol (Nycomed Pharm, Oslo,
Norway) density gradient using ultracentrifugation, and fractions of
300 l were collected from the bottom of the gradient. To reduce
viscosity of the iodixanol, rAAV-fractionswere diluted 10 timeswith PBS
and reconcentrated on a Centricon-100 concentrator (Amicon). The
rAAV stocks contained 2  1012 particles/ml for rAAV-Agouti-
woodchuck posttranslational regulatory element (WPRE) and 2 1011
particles/ml for rAAV-EGFP-WPRE.
In vitro infection, Western blot analysis, and MC receptor activation
assay. HEK 293 cells were infected (multiplicity of infection, 10) with
rAAV-Agouti or rAAV-EGFP. Four days after infection, supernatant was
collected. Aliquots (20 l) of the supernatant were diluted 1:1 with
tricine sample buffer and separated on a 12% Tris/tricine gel. After elec-
trophoresis, proteins were transferred to a nitrocellulose membrane and
blocked by incubation for 1 hr at room temperature with 10% nonfat
milk in Tris-buffered saline/0.1% Tween 20 (TBST). Themembrane was
incubated overnight with rabbit anti-Agouti antibody as the primary
antibody (1:5000 dilution), followed by goat anti-rabbit peroxidase (1:
10,000 dilution) (Jackson ImmunoResearch West Grove, PA) for 60 min
afterwashingwithTBST.AfterwashingwithTBST,HRP-labeled antibodies
weredetectedbychemiluminescence.Agouti- orEGFP-expressingHEK293
cellsweremixedat a1:1 ratiowithHEK293cells cotransfectedwith100ngof
an MC4 receptor expression vector (Oosterom et al., 1999) and 7 g of
Cre-lacZ (Chen et al., 1995). Two days after transfection, melanocortin-
induced(0.01–100nMMT-II)-galactosidaseactivitywasquantifiedusinga
colorimetric assay (Chen et al., 1995). EC50 values of MC-induced
-galactosidase activity in the presence of Agouti- or EGFP-producing cells
were determined by fitting the data to a sigmoidal curve with variable slope
using GraphPad Prism 2.01 for Windows 95/NT (GraphPad Software, San
Diego, CA).
Animals. Male outbred rats [strain Wistar (U:WU)] (body weights
between 240 and 260 gm) were maintained in a 12 hr light/dark cycle
(ambient temperature was 21.0  1.0°C). Food (complete laboratory
chow; Hope Farms, Woerden, The Netherlands) and water were avail-
able ad libitum. After 10 d of baseline recordings (body weight and food
intake), rats were anesthetized with Hypnorm (0.1 ml/100 gm body
weight, i.p.; Janssen Pharmaceutica, Beersse, Belgium) and Dormicum
(0.05 ml/100 gm body weight, i.m., Hoffman-LaRoche, Mijdrecht, The
Netherlands). Stereotaxic bilateral injections of rAAV-Agouti and rAAV-
EGFP (as a control) were performed in the PVN [1.8 mm anteropos-
terior (AP), 0.3 mm mediolateral (ML), and 8.6 mm dorsoventral
(DV), using bregma as a reference for AP and ML coordinates and the
skull as a reference for DV coordinates], DMH (2.5 mm AP, 0.3 mm
ML, and 8.4 mm DV), LH (2.56 mm AP, 1.55 mm ML, and 9.32 mm
DV), and 0.76 mm anterior of the PVN region (1.04 mm AP, 0.3 and
0.3 mmML, and8.6 mmDV). During 5 min, 1 l of virus (2 108
particles) was injected per site. After each injection, the needle remained
stationary for an additional 5 min and was then removed.
After surgery, food intake and body weight were monitored at least
every third day for no less than 42 d. Animals were then provided with a
high-energy diet (HED) with a high-fat content for 10 consecutive days
(energy content of diets, 3731.9 kcal/kg in regular chow and 4655 kcal/kg
in the HED; percentage energy derived from carbohydrate/protein/fat in
diets, 63/23/14 in regular chow and 19/19/62 in the HED). After these
10 d, all animals were anesthetized with sodium pentobarbital and per-
fused with saline, followed by perfusion with 4% paraformaldehyde
(PFA). Brains were postfixed overnight with 4% PFA and cryoprotected
in a 25% sucrose solution (overnight). Brains were than frozen in cold
isopentane (30°C for 20 sec). Cryostat sections (20 m) were used for
Agouti immunohistochemistry and for in situ hybridization.
Agouti antibody staining. After pretreatment with 4% fetal calf serum
and 0.3%H2O2 in PBS, sectionswere incubatedwith a rabbit anti-Agouti
antibody (1:5000, overnight at 4°C). After a 1 hr incubation with a sec-
ondary goat anti-rabbit-biotinylated antibody (1:100) (Jackson Immu-
noResearch), sections were incubated with ABC (1:500) (Vector Labora-
tories, Burlingame, CA) for 1 hr at room temperature. Sections were then
treated with diaminobenzidine (1:100) (Sigma, St. Louis, MO) in PBS
with 30% H2O2 in PBS for 10 min. All immunohistochemistry steps
described above were followed by a three times rinse with PBS of at least
5 min per rinse. Slides were dehydrated in serial ethanol solutions,
cleared with xylene, and coverslipped. For histological confirmation of
the injection site, Agouti immunoreactivity in the injection sites was
confirmed in every other section throughout the hypothalamus for all
animals.
In situ hybridization. Pretreated 20 m cryostat sections from rat hy-
pothalamus were hybridized with 35S-labeled antisense mRNA probes
for Agouti-related protein (AgRP),NPY,MCH, and orexins according to
van der Kraan et al. (1998). mRNA expression in the arcuate nucleus (for
NPY and AgRP) and lateral hypothalamus (for MCH and hypocretins/
orexins) was quantified using MCID-M5 (Imaging Research, St. Ca-
tharines, Ontario, Canada). mRNA levels are expressed in counts per
minute as calculated from a standard curve of diluted probe mix on the
same film on which the slides were measured. From each animal, two
measurements per probe were taken in the region of interest (arcuate
nucleus and lateral hypothalamus) and subsequently averaged to calcu-
late the mean counts per minute per probe for that region.
Statistics. All data are expressed as mean  SEM. Differences in food
intake, body weight, and mRNA expression levels were assessed using
one-way and repeated-measure ANOVA, unless indicated differently in
the text. In the presence of a significant main effect, the analysis was
followed by Tukey’s (SPSS for Windows, version 9.0; SPSS, Chicago, IL)
contrasts ( 0.05).
Ethical commission. Animal research and care was approved by the
Ethical Commission on Laboratory Animal Experiments of the School of
Medicine, University of Utrecht (Utrecht, The Netherlands).
Results
An rAAV-Agouti vector under the control of a CMV promotor
was generated and tested for efficacy to release the Agouti protein
after infection. In contrast to the media of HEK 293 cells infected
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with the rAAV-EGFP control particles,
substantial Agouti protein was demon-
strated in the media of cells infected with
the rAAV-Agouti particles by Western
blot analysis (Fig. 1A). Thus, Agouti was
produced and released from cells infected
with rAAV-Agouti viral particles. Injec-
tion of 1 l of the rAAV-Agouti particles
(2  108 particles) in selected brain re-
gions resulted in local Agouti expression
(Fig. 1B,C). It was confirmed that Agouti
protein was expressed for at least 60 d with
an expression onset as early as 3 d after
injection. No Agouti staining in target
sites of these neurons, such as the brain-
stem, was observed. To demonstrate effi-
cacy of Agouti to antagonize MC-induced
receptor activation, HEK 293 cells ex-
pressing either EGFP or Agouti were
mixed with cells transfected with human
MC-4 receptor and with Cre-lacZ (as a re-
porter for receptor stimulation), mimick-
ing rAAV-Agouti infection in vivo with
cells releasing Agouti in the surrounding
of cells that express MC-4 receptors. The
EC50 value ofMC-inducedMC-4 receptor
stimulated Cre-lacZ in HEK 293 cells was
right-shifted from 0.25 to 1.1 nM. This in-
dicates that the released Agouti protein
functionally antagonizes MC-4 receptor
signaling.
Expression of the MC4-R antagonist Agouti in the PVN of
adult rats increased body weight and food intake within 7 d after
the injection of rAAV-Agouti compared with injection of rAAV-
EGFP (Fig. 2A,B). These elevated levels of food intake and body
weight gain remained for over 6 weeks. In this episode, PVN-
injected rats ate on average 4 gm/d more than controls, resulting
in a 50% increase in body weight gain ( p 0.0001). Histological
confirmation of Agouti expression indicated that injections lead-
ing to Agouti expression just outside of the PVN region (missed;
n 5) were insufficient to induce the rapid onset hyperphagia, in
contrast to animals with confirmed PVNAgouti expression (n
7) [average food intake for the last 3 d of the 6 weeks of ad libitum
access to regular chow was 24.8 0.6 gm (PVN-EGFP control),
24.6 0.8 gm (missed PVN-Agouti), and 29.0 0.7 gm (PVN-
Agouti)]. Despite dense levels of MC4-R expression, we show
that Agouti expression in the LH, in contrast to that in the PVN,
did not affect body weight and food intake when animals were
maintained on regular chow (Fig. 2C,D).
Unlike the rapid onset of obesity in PVN animals, onset was
delayed when Agouti was expressed in the DMH. In the first 3
weeks after the injection, DMH-injected animals had similar lev-
els of food intake and bodyweight when comparedwith controls.
Thereafter, however, DMH-injected animals increased food in-
take and ate on average 2.5 gm/d more than controls. This re-
sulted in a 30% increase in body weight gain ( p 0.0001) (Fig.
2E,F). Because the DMH is located only 0.76mmposterior from
the PVN region involved in acute onset obesity, we investigated
whether the delayed onset inDMHanimals was a consequence of
Agouti leakage to the PVN region. To exclude this possibility, we
showed that rAAV-Agouti did not increase food intake and body
weight when injected 0.76 mm anterior, instead of posterior, to
the PVN region. To also exclude the possibility that the delayed
onset of increased food intake and body weight resulted from a
later start time of expression of AAV constructs in the DMH
when compared with the PVN, we confirmed that Agouti was
expressed in the DMH as early as 3 d after the injection.
High-fat food is known to contribute to the development of
obesity. Because Agouti expression in the LH did not contribute
to food intake and body weight during regular chow, all animals
weremaintained on a high-energy diet with a high-fat content for
10 consecutive days to test diet responsiveness. This high-fat diet
resulted in increased body weight gain in LH-Agouti animals
when compared with LH-EGFP controls (Fig. 3A). Usually, this
diet results in a suppression of daily food intake because of the
higher caloric density of food (Adolph, 1947). However, animals
with Agouti expression in the LH had a far less pronounced sup-
pression of food intake when theywere switched to a high-fat diet
when compared with LH-EGFP control, DMH, and PVN-Agouti
injected animals. Indeed, actual comparison of caloric intake
during regular and high-fat diet in LH-Agouti and LH-EGFP
control animals revealed that LH-Agouti animals had an in-
creased caloric intake during the high-fat diet (Fig. 3B).
Local long-termAgouti expression in the PVN,DMH, and LH
differentially induced hyperphagia and accelerated body weight
gain without apparent changes in central neuropeptide systems
that are known to stimulate food intake. We found that both
AgRP and NPY mRNA levels in arcuate nucleus neurons, as well
as MCH and orexin mRNA expression in the lateral hypothala-
mus, were not affected after long-term Agouti expression in the
PVN, DMH, or LH (Fig. 4).
Discussion
Our results show that Agouti expression in the PVN induced a
rapid onset of hyperphagia and body weight gain. This was not
unexpected, because a single local injection of aMC agonist stim-
ulates food intake (Kim et al., 2000; Wirth et al., 2001). Surpris-
Figure 1. Agouti expression and secretion after infection with the rAAV-Agouti vector. Western blots (A) of media from HEK
293 cells thatwere infectedwith theAAV-EGFP control (left lane) andAAV-Agouti (right lane) vectorswere stainedwith anAgouti
antibody. No Agouti was observed in the media of cells infected with the AAV-EGFP controls (A). Infection by rAAV-Agouti in
neurons of the PVN of the hypothalamus (B) and LH ( C) led to local expression of Agouti without staining observed outside of the
injected target sites. 3v, Third ventricle; mfb, medial forebrain bundle. Regions (B, C) were defined by using the atlas by Paxinos
andWatson (1998).
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ingly, Agouti expression in the DMH caused delayed onset of
increased food intake and body weight, whereas LH-Agouti ex-
pression did not affect body weight on a regular diet but resulted
in diet-induced obesity. Therefore, these data show that MC sig-
naling in different brain regions contributes to different charac-
teristics of the obesity syndrome and that the development of
these characteristics, such as hyperphagia and diet-induced obe-
sity, are under distinct neuroanatomical control in the brain.
These findings open opportunities for additional research aimed
at how these different brain regions control different aspects of
energy homeostasis. Furthermore, the approach taken is readily
available to investigate whether disruption of MC signaling in
other brain regions implicated in regulation of food intake, such
as the dorsal motor nucleus of the vagus nerve, also induce char-
acteristics of the obesity syndrome.
Here we show that Agouti expression in the PVN and DMH
both stimulates food intake and body weight; however, the tim-
Figure 2. Agouti expression in the PVN and DMH results in acute and delayed onset long-
term hyperphagia-induced obesity, respectively. Body weight (bw) gain (A) and food intake
(B) (both averaged over 3 d segments) are increased in animals with Agouti expression in the
PVN when compared with EGFP control PVN-injected animals. During ad libitum access to reg-
ular chow, body weight gain and food intake were similar in animals with Agouti expression in
the LH and EGFP control LH-injected animals (C, D). In animals with Agouti expression in the
DMH, the onset of increased bodyweight gain ( E) and food intake ( F) was delayed by 3weeks,
4
in contrast to the acute obesity onset in animals with Agouti expression in the PVN. In the first
3 d after surgery (days 0–3), a decline in body weight gain and food intake was observed in all
animals. Histological verification of Agouti expression was checked for all animals by means of
Agouti immunoreactivity. Animals with Agouti-positive cells in the targeted regions (PVN,
1.80 to2.12 mm from bregma; LH,2.56 to3.80 mm from bregma; DMH,2.56 to
3.14 mm from bregma) [region as defined using the atlas by Paxinos and Watson (1998)]
were used for the analysis and resulted in the shown behavioral data set for these confirmed
groups (n 6–7 per group).
Figure 3. Agouti expression in the LH induced diet-induced obesity. Whereas LH-EGFP con-
trol and LH-Agouti injected animals had similar levels of bodyweight (bw) gain during anormal
diet (body weight gain during the last 10 d of the normal diet), body weight gain significantly
increased in animals with Agouti expression in the LH during 10 d of access to a high-fat diet
(compared with body weight on the day before the high-fat diet) (A). This increased body
weight gain in LH-Agouti injected animals related to increased caloric intake in LH-Agouti
animals during the high-fat diet (B). **p 0.0001, different from all other conditions; ap
0.006, different from LH-EGFP during normal diet; bp 0.003, different from LH-EGFP during
high-fat diet.
Figure 4. Hypothalamic mRNA expression levels of the orexigenic neuropeptides AgRP and
NPY in the arcuate nucleus, as well as MCH and orexins in the lateral hypothalamus. After
long-term local expressionofAgouti in thePVN,DMH,andLH,nodifference inmRNAexpression
levelswereobservedwhencomparedwithEGFPcontrols (inbrainsof rats fromFigs. 2, 3).mRNA
expression levels are expressed as a percentage from the EGFP controls. Because region-specific
EGFP controls were not different in gene expression levels, their expression levels were pooled
for the analysis.
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ing of hyperphagia onset is significantly delayed in the DMH
when compared with the PVN. Because these regions are closely
located to each other, the DMH effects of Agouti may be ex-
plained by leakage of Agouti from theDMHto the PVN, resulting
in a delayed onset of the PVN-induced hyperphagia. However, an
acute or a delayed onset of hyperphagia and body weight increase
were not found in animalswithAgouti expression just outside the
PVN (missed PVN injections) or 0.76 mm anterior to PVN (the
DMH is located 0.76 mm posterior to PVN). Therefore, these
data make it unlikely that the delayed onset of hyperphagia after
DMH-Agouti expression was caused by leakage of Agouti from
the DMH to the PVN and indicate that disruption of MC signal-
ing in the DMH does not result in immediate increased food
intake and body weight, such as observed after AAV-Agouti in-
jection in the PVN. Additional studies can now focus on the
mechanisms underlying this late onset obesity and the role of the
DMH therein.
The present data show that inhibition of MC signaling in the
LH selectively accelerates the development of obesity on a high-
fat diet by affecting caloric intake. LH-Agouti injected animals
had similar caloric intake and body weight gain on regular chow.
However, Agouti expression in the LH resulted in an increased
caloric intake and subsequent body weight gain on a high-fat diet
when compared with LH-EGFP controls. Therefore, our data
provide evidence that the LH is an important brain region for the
protection against diet-induced obesity rather than for the induc-
tion of hyperphagia (as shown in the PVN). The increased caloric
intake after inhibition ofMC signaling in the LHmay result from
impaired satiety signaling during intake of high-fat food. In ad-
dition, recent studies suggest that the LH region integrates infor-
mation about energy status and reward (Fulton et al., 2000). Ad-
ditional behavioral and anatomical studies are needed to
demonstrate how energy intake, energy expenditure, and possi-
ble reward mechanisms are integrated in the LH.
To further characterize the different mechanisms underlying
the brain region-specific forms of Agouti-induced obesity,
mRNA gene expression levels of known orexigenic neuropep-
tides (NPY, AgRP, MCH, and orexins) were measured in several
brain regions. Although local and long-termAgouti expression in
the PVN, DMH, or LH hadmarked and different effects on body
weight and food intake, no obvious changes inmRNA expression
levels of these known orexigenic neuropeptide systems were ob-
served. One interpretation of these results is that brain region-
specific disruption of MC-R signaling by Agouti leading to hy-
perphagia and accelerated weight gain on a high-fat diet is
independent of regulation of the hypothalamic orexigenic neu-
ropeptidesNPY,AgRP,MCH, andorexins. This idea is consistent
with previous data showing that blockade of MC-R signaling,
although causing hyperphagia and obesity, did not lead to alter-
ations in expression levels of a number of hypothalamic neu-
ropeptides including, for example, NPY expression in the arcuate
nucleus (Kesterson et al., 1997; Adage et al., 2001). We cannot
rule out, however, that induction of Agouti expression did tran-
siently alter expression of, at least, some of these neuropeptide
systems, allowing these animals to become obese. Therefore, a
more extensive analysis of time-dependent changes in these neu-
ropeptide systems and other metabolic parameters may be re-
quired to further study physiological changes related to the ob-
served brain region-specific forms of obesity induced by Agouti.
Together, these findings suggest that a single neuropeptide
system, such as the MC system, regulates different adaptive be-
havioral and physiological strategies to alter an organism’s energy
balance toward a certain direction (e.g., energy conservation) in
distinct brain nuclei. The brain homolog for Agouti, AgRP, is
expressed in the arcuate nucleus of the hypothalamus and inner-
vates a wide variety of brain regions, such as the PVN, DMH, and
LH. These arcuate nucleus neurons respond to sudden changes in
peripheral molecules, such as leptin, glucose, and insulin, that
provide information about the energy status of an organism.
Starvation, for example, leads to a drop in leptin levels (Ahima et
al., 1996) and subsequent increase in AgRP gene expression
(Hahn et al., 1998). Thiswill result in a simultaneous activation of
distinct brain regions that, as indicated by the present study,
regulate brain region-specific aspects of physiological processes,
each contributing separately to energy conservation.
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